Introduction {#s1}
============

The incidence of coronary heart disease is greater in men than in premenopausal women of the same age, but increases in frequency after menopause, an effect that has been attributed, at least in part, to estrogens [@pone.0008242-Mendelsohn1]. Estrogens have been used as contraceptive agents or as principal constituents of hormone replacement therapy formulations in postmenopausal women, 17β-estradiol being the most widely used molecule. The cardiovascular protective effect detected in a considerable number of observational clinical studies [@pone.0008242-BarrettConnor1] has not been confirmed by more recent randomized placebo-controlled trials designed to study the effects of hormonal therapy in either secondary [@pone.0008242-Hulley1], [@pone.0008242-Grady1] or primary [@pone.0008242-Rossouw1] prevention. It should be stated that the clinical trials of estrogen therapy for the treatment of cardiovascular disease are largely flawed (e.g., hormone replacement therapy started too late in menopause). Moreover, a number of studies have demonstrated a favorable profile for estrogens in both experimental animal as well as *in vitro* models [@pone.0008242-Turgeon1].

Endothelium is crucial to the modulation of vessel tone and to the control of platelet adhesion and aggregation, two key factors in the initiation and development of atherosclerosis [@pone.0008242-Ross1]. Endothelium, including human umbilical vein endothelial cells (HUVEC), expresses both types of estrogen receptors (ER), α and β, and the actions of estrogens on endothelium have been exhaustively studied [@pone.0008242-Mendelsohn2]. Moreover, clinical and experimental data support the consideration of endothelium as a target for sexual hormones [@pone.0008242-Mendelsohn3]. Estradiol effects on partial gene expression in endothelial cells have frequently been studied, but there is a lack about its effects on the whole gene expression profile.

Microarrays are high-throughput genomic tools that allow the comparison of global expression changes in thousands of genes between different experimental conditions in cell/tissue analysis, and they have been widely adopted for analyzing the global gene expression profiles *in vivo* and *in vitro* [@pone.0008242-Trevino1]. Recent studies have demonstrated the ability of this technology for investigating molecular pathophysiological mechanisms involved in a variety of human diseases. For instance, microarray technology has been used as a novel experimental approach to analyze alterations in gene expression in different cardiovascular diseases [@pone.0008242-Archacki1], atherosclerosis [@pone.0008242-Hiltunen1] and experimental stroke in rats [@pone.0008242-Graham1].

Microarray technology offers the possibility of exploring a large number of candidate genes which are modified by estrogens. The present study aims to explore gene expression modification, mainly focused on candidate genes that may regulate the vascular effects of estrogens, in cultured human endothelial cells exposed to physiological concentrations of estradiol by using microarrays, thus providing new information to the available body of knowledge about the influence of estradiol on the vascular wall.

Materials and Methods {#s2}
=====================

Ethics Statement {#s2a}
----------------

This investigation conforms to the principles outlined in the Declaration of Helsinki, was approved by the Ethical Committee of Clinical Research of the University Clinical Hospital of Valencia, and written informed consent was obtained from all donors.

Cell Culture and Experimental Design {#s2b}
------------------------------------

Primary HUVEC were isolated, grown, and identified as described earlier [@pone.0008242-Hermenegildo1] in human endothelial cell-specific Medium EBM-2 (Lonza, Basel, Switzerland), supplemented with EGM-2 (Lonza), in an incubator at 37°C with 5% CO~2~.

Cells from passages 4 to 6 were seeded onto 25 cm^2^ flasks for mRNA isolation. When cells were at 75% of confluence, culture medium was exchanged for a phenol red--free Medium 199 (GIBCO, Invitrogen, Barcelona, Spain) supplemented with 20% charcoal/dextran-treated fetal bovine serum (GIBCO), EGM-2, pyruvic acid and antibiotics ("hormone free medium") to avoid any estrogenic activity and maintained for 24 hours. Then, culture medium was eliminated and replaced by phenol red-free medium 199.

Cells were exposed to different concentrations (range: 0,01 -- 100 nmol/L) of 17β-estradiol (Sigma, Alcobendas, Spain) by serial dilutions of a stock solution with phenol red-free medium. The pure anti-estrogen ICI182780 (1 µmol/L; Biogen, Madrid, Spain) was used to evaluate whether the observed effects were mediated by ER modulation. Control cells were exposed to the same vehicles of estradiol (0.1% ethanol) or ICI182780 (0.1% DMSO). All treatments were added in hormone free medium and experiments were performed at 75--80 % of confluence.

RNA Isolation and Genechip Expression Analysis {#s2c}
----------------------------------------------

To carry out the microarray experiments, HUVEC from 9 separate cultures were exposed to control (0.1% ethanol) and 1 nmol/L estradiol treatments for 24 h. Total cellular RNA was extracted by using the TRIzol® reagent (Invitrogen, USA) following the manufacturer\'s instructions. RNA integrity was assayed by means of the 2100 Bioanalizer (Agilent Technologies, Santa Clara, CA, USA). Equal amounts of RNA extracted from 3 control- or 3 estradiol-treated cultured flasks obtained from three different cultures were pooled, achieving three biological replicates of the control and three that were treated with estradiol. Therefore, a total number of 6 microarrays were developed (3 control pools, named C1, C2, C3, and 3 estradiol-treated pools named E1, E2 and E3). Five micrograms of total RNA were amplified and labeled according to GeneChip Expression Analysis Technical Manual (Affymetrix Ltd, UK). The concentration of biotinylated and fragmented cRNA was measured using the 2100 Bioanalizer (Agilent Technologies). Twenty micrograms of fragmented biotinylated cRNA were used to prepare the hybridization cocktail and subsequently hybridized for sixteen hours to the Human Genome U133A plus 2.0 microarrays, which analyzes the expression level of over 47000 transcripts and variants. Arrays were washed and stained according to the EukGene_ws_2v5 in the Fluidics Station (Affymetrix) and scanned using the GeneChip scanner 3000. Affymetrix\'s GeneChip Operating Software (GCOS, Affymetrix) was used to obtain and analyze images.

Files obtained from GCOS (.cel) were used to analyze significant changes in expression profiles of different experimental groups using the dCHIP Analysis Software and the SpotFire Decision Site software. Data were normalized using the Invariant Set Method described earlier [@pone.0008242-Li1] and modeled using the PM/MM model. Then, ANOVA was used to find significant changes among experimental groups. False Discovery Rate (FDR) was used to discriminate false positives in the multivariant system. Only adjusted p-values \<0.05 were considered significant. Global differences between different samples were measured by Principal Component Analysis (PCA) and Linear Discrimination Analysis (LDA). Hierarchical Cluster was used to analyze expression profiles of different samples, and was carried out using UPGMA (Unweighted Pair Group Method with Arithmetic Mean) analysis, with an ordering function based on the input rank. Data are represented as a dendrogram, with the closest branches of the tree representing arrays with similar gene expression patterns. Gene Onthology Browser (Nettaffyx Analysis Center, Affymetrix) was used to classify genes according to functionality context. Finally, relationships among data were screened using the Pathway Architect software (Stratagene, La Joya, CA, USA). All data discussed in this publication is MIAME compliant and that the raw data has been deposited in NCBI\'s Gene Expression Omnibus [@pone.0008242-Edgar1], a MIAME compliant database, and are accessible through GEO Series accession number GSE16683.

Network Identification and Canonical Pathway Analysis {#s2d}
-----------------------------------------------------

List of genes significantly regulated by estrogen were analyzed using Ingenuity Pathways Analysis (IPA) software (Ingenuity Systems, Redwood City, CA, USA). IPA uses a variety of computational algorithms to identify and establish cellular networks that statistically fit the input gene list and expression values from experiments. Data sets containing the Affymetrix probe set identifiers and fold changes of genes were overlaid onto a global molecular network developed from information contained in the database. Networks were then algorithmically generated based on their connectivity and a score was assigned. The score is used to rank networks according to how relevant they are to the genes in the input dataset. Each network or pathway was arbitrarily set to have a maximum of 35 focus genes. Genes or gene products are represented as nodes, and the biological relationship between two nodes is represented as an edge. The intensity of the node color indicates the degree of up- (red) or down- (green) regulation.

Canonical pathways analysis identified the pathways, which were most significant to the input data set. The significance of the association between the data set and the canonical pathway was determined based on two parameters: (1) a ratio of the number of genes from the data set that map to the pathway divided by the total number of genes that map to the canonical pathway and (2) a P value calculated using Fischer\'s exact test determining the probability that the association between the genes in the data set and the canonical pathway is due to chance alone.

Quantitative Real Time PCR (QRT-PCR) Assays {#s2e}
-------------------------------------------

Reverse transcription (RT) was carried out using SuperScript^TM^ II Synthesis System for RT--PCR (Invitrogen) by using a personal Mastercycler Eppendorf Thermocycler (Eppendorf, Hamburg, Germany). Different samples than that used for microarrays experiments were used to perform the QRT-PCR assays. One microgram of total RNA was reverse-transcribed to cDNA following the manufacturer\'s instructions. For each RT, a blank was prepared using all the reagents except the RNA sample (replaced with an equivalent volume of diethylpyrocarbonate (DEPC)-treated water) and also used as non-template control in real-time PCR experiments.

Quantitative real-time PCR (QRT-PCR) was done with SYBR-Green PCR Master Mix or TaqMan Universal Mastermix (Applied Biosystems, Fosters City, CA, USA). In the case of DHCRA7, PLA2G4A and PLA2G4B, the PCR reaction mix was prepared in 0.2 mL RNase free tubes by adding a volume of TaqMan Universal PCR Master Mix and TaqMan Gene Expression Assay ([Table 1](#pone-0008242-t001){ref-type="table"}). The sample of cDNA obtained from the RT was incorporated into the necessary quantity of DEPC-treated water to get a final concentration of 40 ng approximately (range: 10--100 ng). The GADPH gene was used as endogenous control. The appropriate volume of each reaction mixture was transferred to a reaction plate which was then placed in the 7900HT Fast Real-Time PCR System (Applied Biosystems) with the appropriate thermal cycling conditions (50°C/2 min, 95°C/10 min, 40 Cycles; 95°C/15 s, 6°C/1 min).
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###### List of abbreviations and primers used for RT-PCR.

![](pone.0008242.t001){#pone-0008242-t001-1}

  Gene                                          Abbreviation   Accession no.    Custom Primer                           Sequence                          Fragment (bp)
  -------------------------------------------- -------------- --------------- ----------------- -------------------------------------------------------- ---------------
  Ciclooxigenase-1                                 COX-1         AF440204      Forward Reverse   5′-TACTCACAGTGCGCTCCAAC-3′ 5′-GCAACTGCTTCTTCCCTTTG-3′         168
  Ciclooxigenase-2                                 COX-2          D28235       Forward Reverse    5′-ATCATAAGCAGGGCCAGCT-3′ 5′-AAGGCGCAGTTTACGCTGTC-3′         101
  Dimethylarginine dimethylaminohydrolase-1        DDAH-1        BC_033680     Forward Reverse   5′-GGACAAATCAACGAGGTGCT-3′ 5′-TAGCGGTGGTCACTCATCTG-3′         193
  Dimethylarginine dimethylaminohydrolase-2        DDAH-2        NM_013974     Forward Reverse    5′-GATCTGGCCAAAGCTCAAAG-3,5′-CAACCCAGGACGAAGAAAGA-3′         573
  *Glyceraldehyde 3-phosphate dehydrogenase*      *GADPH*        NM_002046     Forward Reverse   5′-CTGCTCCTCCTGTTCGACAGT-3′ 5′-CCGTTGACTCCGACCTTCAC-3′        100

  Gene                                           Gene     Accesion no.   TaqMan® Gene Expression Assays   Fragment (bp)
  -------------------------------------------- --------- -------------- -------------------------------- ---------------
  7-dehydrocholesterol reductase                 DHCR7    NM_001360.2            Hs00154732_m1                 85
  Phospholipase A2, group IVA                   PLA2G4A   NM_024420.2            Hs00233352_m1                 69
  Phospholipase A2, group IVB                   PLA2G4B   NM_005090.2            Hs00192661_m1                 71
  *Glyceraldehyde 3-phosphate dehydrogenase*    *GADPH*   NM_002046.3          endogenous control              122

In the case of COX-1, COX-2, DDAH-1 and DDAH-2, a QRT-PCR was performed using an ABI PRISM 7700 Sequence Detection System (Applied Biosystems) with a heated lid (105°C), an initial denaturation step at 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. To amplify cDNA, the RT samples were diluted 1/10. In each reaction, a total of 1 µL from each RT tube was mixed with 12.5 µL of SYBR Green PCR master mix (Applied Biosystems) containing nucleotides, Taq DNA polymerase, MgCl~2~ and reaction buffer with SYBR green; 1.5 µL of 5 µmol/L adequate primers and DEPC-treated water were added to a final volume of 25 µL. In parallel, 5-fold serial dilutions of well-known DNA concentrations were run as calibration curves. Primers ([Table 1](#pone-0008242-t001){ref-type="table"}) were designed using the Primers Express Software (Applied Biosystems) and synthesized by Custom Primers (Life Technologies, Barcelona, Spain).

Data were analysed with the ABI PRISM Sequence Detection v. 1.7 analysis software (Perkin Elmer, Nieuwerkerk, The Netherlands). To validate a QRT-PCR, standard curves with r\>0.95 and slope values between −3.1 and −3.4 were required. Gene expression was relative quantified based on the work of Pfaffl [@pone.0008242-Pfaffl1]. In some samples, PCR bands were purified using a MiniElute PCR Purification Kit (Qiagen, Valencia, CA, USA) and then sequenced to prove that the amplified products corresponded to previously published sequences. Agarose gel electrophoreses were also performed to demonstrate that QRT-PCR yielded a unique band.

Immunoblotting {#s2f}
--------------

HUVEC were treated in 25 cm^2^ flasks for 24 hours with the desired products. A volume of 150 µL of lysis buffer (0.1 % triton X-100, 0.5 % sodium deoxicholate acid, 0.1 % Sodium Dodecyl Sulphate (SDS), 0.1% phenylmethanesulphonylfluoride or phenylmethylsulphonyl fluoride (PMSF), in 100 mL of phosphate saline buffer (PBS) containing protease inhibitors: 1 µg/mL leupeptin, 0.5 µg/mL pepstatin and 1 µg/mL bestatin) was added and maintained at 4°C for 30 minutes. Then, cells were collected using a cell scraper, boiled for 5 minutes and sonicated for 10 seconds. Protein content was measured [@pone.0008242-Lowry1] and samples were frozen at --20°C until assay.

Equal amounts of protein (60--80 µg) were then separated by 10% of SDS-Polyacrylamide gel electrophoresis, and the protein was transferred to PVDF sheets (Biorad, Spain). Immunostaining was achieved using specific antibodies anti-ERα (sc-8002; Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-ERβ (sc-8974; Santa Cruz Biotechnology), anti-COX-1 (cat 236003; Calbiochem, Germany), anti-COX-2 (cat 160107; Cayman Chemical), anti-DDAH-I (PC716; Calbiochem) or anti-DDAH-II (PC717; Calbiochem). Development was performed with alkaline-phosphatase-linked appropriate secondary antibodies (from Sigma), followed with nitroblue tetrazolium (NBT)/5-Bromo-4-Chloro-3-Indolyl Phosphate, p-toluidine salt (BCIP) color development reaction. Blots were digitalized using a Gelprinter PLUS (TDI, Madrid, Spain), and the densities of spots were analyzed with the program Image Gauge 4.0 (Science Lab. 2001). Equivalent protein loading and transfer efficiency were verified by staining for β-actin (Sigma).

Prostacyclin Assay {#s2g}
------------------

After treatment with the desired products, medium was collected and stored at --20°C until prostacyclin was measured. Culture wells were then washed with PBS and adherent cells were collected in 0.5 N NaOH for protein determination by the modified Lowry\'s method using bovine serum albumin as standard [@pone.0008242-Lowry1].

The amount of prostacyclin produced, calculated as the concentration of stable hydrolysis product, 6-keto-prostaglandin-F1α, was assessed in duplicate by a commercial EIA kit (Cayman Chemical). Prostacyclin production was expressed as ng prostacyclin/mg protein.

Isolation and Measurement of Asymmetric Dimethylarginine (ADMA) {#s2h}
---------------------------------------------------------------

After 24 hours of incubation with the desired treatments, medium was collected and stored at --20°C until asymmetric dimethylarginine (ADMA), a major endogenous inhibitor of nitric oxide synthase (NOS), quantification. Culture wells were then washed with PBS and adherent cells were collected in 0.5 N NaOH solution for protein determination [@pone.0008242-Lowry1].

Measurement of ADMA was accomplished by high-performance liquid chromatography (HPLC) as described earlier [@pone.0008242-Monsalve1]. In brief, ADMA from 1 mL of culture medium was purified with Bond Elut SCX columns (Varian Inc., Palo Alto, CA, USA) and eluted with 4 mL of methanol containing 30% distilled water and 2% triethylamine. The eluent was then evaporated to dryness at 60°C, and the dried extract was redissolved in running buffer. HPLC was carried out on a Shimadzu chromatography system (Shimadzu Corporation, Kyoto, Japan). Separation of ADMA was achieved with a 250×4.6-mm (inner diameter), 5-µm "Kromasil C18" analytical column (Scharlau, Barcelona, Spain) using 25 mM phosphoric acid containing 10 mM hexane sulphonic acid and 1 % \[v/v\] acetonitrile, pH 5.0. The analysis was carried out at a flow rate of 1.3 mL/min and the absorbance monitored at 200 nm. Concentrations of ADMA in the samples were determined by comparison with standards (Sigma, Alcobendas, Spain). ADMA production was expressed as nmol/mg protein.

Nitric Oxide (NO) Production {#s2i}
----------------------------

After 24 hours of incubation with the desired treatments, cells were washed and incubated with HEPES buffer (5 mM HEPES containing (in mM) 140 NaCl, 5 KCl, 2 CaCl~2~, 1 MgCl~2~ and 10 glucose, pH adjusted to 7.4), for 120 min. Then, incubation medium was collected, culture wells were washed with PBS, and adherent cells were collected in 0.5 N NaOH solution for protein determination [@pone.0008242-Lowry1].

Endothelial NO production was determined in culture medium using the ISONOP nitric oxide sensor (World Precision Instruments, Sarasota, FL, USA), an amperometric sensor specific for NO, as described earlier [@pone.0008242-Monsalve1]. A chemical titration calibration was performed with use of an acidic iodide solution (0.1 mol/l H~2~SO~4~, 0.14 mol/l K~2~SO~4~, 0.1 mol/l KI) against varied volumes of KNO~2~. NO was formed stoichiometrically and measured directly. The quantity of NO was expressed as nmol/mg protein.

Statistical Analysis {#s2j}
--------------------

Values shown in the text and figures are mean ± SEM. ANOVA test was applied for comparisons of mean, and then Bonferroni\'s test was performed. P values\<0.05 were considered significant. The statistical analysis was carried out using the Prism 4 software (GraphPad Software Inc., San Diego, CA, USA).

Results {#s3}
=======

Identification of Global Gene Expression Changes in Estradiol--Treated HUVEC {#s3a}
----------------------------------------------------------------------------

The gene expression profile of human vascular cells treated with or without estradiol was assessed by using the Human Genome U133A plus 2.0 microarray technology from Affymetrix. A total of 1886 genes passed the ANOVA analysis, with fold changes between 2.99 and −5.34. [Table 2](#pone-0008242-t002){ref-type="table"} (online supporting information) summarizes most differentially expressed genes between control and estradiol treated samples. Only genes with more than a 1.9-fold change were included. As expected, the list of genes became greater as a more permissive fold-change was selected. Only 4 genes (∼14%) were up-regulated and 25 (∼86%) were down-regulated when the fold-change was higher than 2.5. By decreasing the fold-change, the number of genes regulated by estradiol increased, and there was a tendency to equate the percentage of genes up-regulated and down-regulated. For instance, with a fold-change higher than 1.9, 187 genes were significantly regulated: 95 (∼50%) were up-regulated and 92 (∼50%) were down-regulated.
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###### Genes that changed more than 1.9-fold with estradiol.

![](pone.0008242.t002){#pone-0008242-t002-2}

  probe set                                                   gene                                               Accession   Control mean   Control SD   Estradiol mean   Estradiol SD   fold change   P value
  --------------- --------------------------------------------------------------------------------------------- ----------- -------------- ------------ ---------------- -------------- ------------- ---------
  212969_x\_at                                    hypothetical protein FLJ35827                                  BE222618       175,19        19,45          500,79          31,72          2,86       0,00342
  223967_at                                            angiopoietin-like 6                                       AF230330       30,98          8,72          86,64            5,75           2,8       0,02964
  212064_x\_at              MYC-associated zinc finger protein (purine-binding transcription factor)             AI471665       186,55        15,26          505,1           107,26         2,71       0,03497
  203442_x\_at                                    hypothetical protein FLJ35827                                  AA478965       195,81         7,93          504,02          44,58          2,57       0,01052
  224182_x\_at           sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6B         AF293363       68,13         17,43          169,76          12,74          2,49       0,01574
  209079_x\_at                                 protocadherin gamma subfamily C, 3                                AF152318       203,67        43,44          503,57          126,44         2,47       0,02558
  227463_at                        angiotensin I converting enzyme (peptidyl-dipeptidase A) 1                    AW057540       69,93         12,41          170,95          17,15          2,44       0,03837
  200707_at                                     protein kinase C substrate 80K-H                                 NM_002743      221,54        57,51          531,35          19,47           2,4       0,01438
  240786_at                                       Notch homolog 4 (Drosophila)                                   AI341271       52,66          5,54           125            14,98          2,37       0,03691
  204693_at                               CDC42 effector protein (Rho GTPase binding) 1                          NM_007061      115,37        10,39          270,64          34,17          2,35       0,02829
  201050_at                                             phospholipase D3                                         NM_012268      274,9         34,99          647,38          19,89          2,35       0,00206
  201396_s\_at                small glutamine-rich tetratricopeptide repeat (TPR)-containing, alpha              NM_003021       166          16,76          389,34          54,20          2,35       0,01439
  202017_at                               epoxide hydrolase 1, microsomal (xenobiotic)                           NM_000120      85,85         19,59          200,8           23,62          2,34       0,04111
  227753_at                                       hypothetical protein FLJ90586                                   R26843        42,02          6,69          98,19            3,76          2,34       0,01451
  230698_at                             MRNA; cDNA DKFZp434H205 (from clone DKFZp434H205)                        AW072102       42,87          8,54          100,33          23,38          2,34       0,04531
  208611_s\_at                         spectrin, alpha, non-erythrocytic 1 (alpha-fodrin)                         U83867        296,27        32,51          689,31          134,18         2,33       0,04892
  209235_at                                            chloride channel 7                                        AL031600       93,14         14,31          214,55          28,67           2,3       0,02221
  211136_s\_at                       cleft lip and palate associated transmembrane protein 1                     BC004865       97,85         34,88          223,39           2,62          2,28       0,03365
  209427_at                                                smoothelin                                            AF064238       148,48        18,65          337,87          36,31          2,28       0,01198
  200859_x\_at                            filamin A, alpha (actin binding protein 280)                           NM_001456      837,96        143,55        1894,68          238,65         2,26       0,00676
  224792_at                                  tankyrase 1 binding protein 1, 182 kDa                              AL566438       83,59         21,44          188,84          16,91          2,26       0,03592
  212127_at                                      Ran GTPase activating protein 1                                 BE379408       148,57        70,00          322,79          15,80          2,17       0,04023
  230112_at                                 membrane-associated ring finger (C3HC4) 4                            AB037820       181,14        83,07          391,8           35,54          2,16       0,02505
  1570318_at                                 Homo sapiens, clone IMAGE:4792986, mRNA                             BC030089       69,31         35,11          148,72          19,06          2,15       0,01849
  205185_at                                  serine protease inhibitor, Kazal type 5                             NM_006846      160,85        55,95          346,46          19,02          2,15       0,01393
  222206_s\_at                                     nicalin homolog (zebrafish)                                   AA781143       91,29          8,04          195,18           9,50          2,14       0,0149
  201373_at                         plectin 1, intermediate filament binding protein 500 kDa                     NM_000445      177,33        23,86          379,57          15,39          2,14       0,01277
  1552667_a\_at                                     SH2 domain containing 3C                                     NM_005489      95,12         13,48          203,46          16,70          2,14       0,04872
  209051_s\_at                           ral guanine nucleotide dissociation stimulator                          AF295773       96,35         14,24          205,2            3,85          2,13       0,02245
  211564_s\_at                                        PDZ and LIM domain 4                                       BC003096       171,62        16,57          364,69           6,42          2,12       0,00636
  240350_at                                             Transcribed locus                                        AI769817       70,76         23,81          148,99          13,00          2,11       0,0374
  201797_s\_at                                       valyl-tRNA synthetase 2                                     NM_006295      95,72         15,28          201,89          17,35          2,11       0,03045
  210428_s\_at                    hepatocyte growth factor-regulated tyrosine kinase substrate                   AF260566       258,31         9,63          543,12          10,09           2,1       0,00539
  202855_s\_at                solute carrier family 16 (monocarboxylic acid transporters), member 3              AL513917       63,41         16,15          132,88           2,87           2,1       0,03614
  202320_at                      general transcription factor IIIC, polypeptide 1, alpha 220 kDa                 NM_001520      90,81          7,28          189,55           4,47          2,09       0,00867
  218051_s\_at                                    hypothetical protein FLJ12442                                  NM_022908      321,65        53,09          667,99          45,65          2,08       0,00553
  200808_s\_at                                                zyxin                                              NM_003461      423,14        13,27          875,16          138,22         2,07       0,02725
  216267_s\_at                                         placental protein 6                                       BF034906       114,34        23,47          234,61           1,02          2,05       0,02765
  219270_at                                       hypothetical protein MGC4504                                   NM_024111      128,82        44,89          262,36          58,64          2,04       0,04536
  219922_s\_at                      latent transforming growth factor beta binding protein 3                     NM_021070      323,66        30,45          661,67          37,35          2,04       0,01075
  1564494_s\_at    procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), beta polypeptide   AK075503       174,37        52,22          355,76          10,91          2,04       0,04303
  201251_at                                          pyruvate kinase, muscle                                     NM_002654      417,25        18,67          851,66          107,61         2,04       0,02554
  45714_at                              host cell factor C1 regulator 1 (XPO1 dependant)                         AA436930       136,61        17,78          276,98          20,76          2,03       0,02748
  212359_s\_at                                              KIAA0913                                              W89120        155,23        17,17          314,75          29,07          2,03       0,01367
  201168_x\_at                             Rho GDP dissociation inhibitor (GDI) alpha                            NM_004309      384,7         36,45          780,38          119,07         2,03        0,023
  223383_at                                          zinc and ring finger 1                                      AL136903       95,87         25,43          195,09           6,64          2,03       0,04785
  215909_x\_at                                 misshapen-like kinase 1 (zebrafish)                               AL157418       145,34        48,17          294,11          68,43          2,02       0,01318
  35265_at                              fragile X mental retardation, autosomal homolog 2                        AF044263       100,19         6,16          201,48           3,24          2,01       0,01011
  226367_at                            Jumonji, AT rich interactive domain 1A (RBBP2-like)                       AA854032       57,11         11,39          114,98          15,75          2,01       0,04725
  229192_s\_at                                    tubulin-specific chaperone d                                   AL096745       170,61        43,32          342,84           9,29          2,01       0,02167
  218522_s\_at                                     BPY2 interacting protein 1                                    NM_018174      165,12        25,92          330,46           5,94            2        0,01544
  200766_at                                 cathepsin D (lysosomal aspartyl protease)                            NM_001909      113,56         1,19          227,52          15,59            2        0,02324
  222155_s\_at                                   G protein-coupled receptor 172A                                 AK021918       74,97         10,34          149,89           2,16            2        0,01724
  227347_x\_at                             hairy and enhancer of split 4 (Drosophila)                            NM_021170      79,62         26,99          159,32          25,99            2        0,03086
  215807_s\_at                                              plexin B1                                            AV693216       72,17         16,35          144,65           1,99            2        0,03366
  202161_at                                             protein kinase N1                                        NM_002741      236,28        21,45          472,79          10,07            2        0,0105
  217937_s\_at                                       histone deacetylase 7A                                      NM_016596      215,95        32,53          429,04           8,40          1,99       0,01042
  209166_s\_at                               mannosidase, alpha, class 2B, member 1                               U68567        199,46        45,12          396,59          46,73          1,99       0,01271
  212968_at                                    radical fringe homolog (Drosophila)                               BF940276       159,88        10,60          317,92          31,31          1,99       0,01304
  209651_at                          transforming growth factor beta 1 induced transcript 1                      BC001830       934,12        83,13         1863,42          337,88         1,99       0,02541
  203926_x\_at               ATP synthase, H+ transporting, mitochondrial F1 complex, delta subunit              NM_001687      330,84        24,63          655,04          26,25          1,98       0,00858
  208890_s\_at                                              plexin B2                                            BC004542       258,45        52,59          510,68          26,53          1,98       0,0126
  217007_s\_at                     a disintegrin and metalloproteinase domain 15 (metargidin)                    AK000667       101,77        21,65          200,18           6,12          1,97       0,02402
  201360_at                          cystatin C (amyloid angiopathy and cerebral hemorrhage)                     NM_000099      384,94         8,11          758,71          49,24          1,97       0,01031
  223050_s\_at                                  F-box and WD-40 domain protein 5                                 BC000850       107,78        10,49          212,4           22,07          1,97       0,02375
  208132_x\_at                                    HLA-B associated transcript 2                                  NM_004638      117,46         6,61          230,97          11,34          1,97       0,01343
  201264_at                                 coatomer protein complex, subunit epsilon                            NM_007263      221,17        57,65          434,02          18,52          1,96       0,04857
  210622_x\_at                               cyclin-dependent kinase (CDC2-like) 10                              AF153430        56,4          9,55          110,79           6,37          1,96       0,04874
  209729_at                                      growth arrest-specific 2 like 1                                 BC001782       133,53        13,55          261,57          28,58          1,96       0,02885
  201102_s\_at                                     phosphofructokinase, liver                                    NM_002626      201,25         8,94          394,24           6,59          1,96       0,0074
  201281_at                                      adhesion regulating molecule 1                                  NM_007002      349,38        56,97          679,65          108,43         1,95       0,02532
  221009_s\_at                                         angiopoietin-like 4                                       NM_016109      224,97        19,81          438,78          85,29          1,95       0,03765
  214175_x\_at                                        PDZ and LIM domain 4                                       AI254547       264,5         24,73          514,92          27,01          1,95       0,00287
  203055_s\_at                           Rho guanine nucleotide exchange factor (GEF) 1                          NM_004706      136,27        20,25          265,87          27,67          1,95       0,03729
  201079_at                                              synaptogyrin 2                                          NM_004710      423,03        23,29          826,04          79,77          1,95       0,01402
  244017_at                        Tax1 (human T-cell leukemia virus type I) binding protein 1                   AI218142       73,03         13,78          142,55           9,52          1,95       0,04703
  40829_at                                     WD and tetratricopeptide repeats 1                                AB028960       114,71        11,89          223,14          33,03          1,95       0,0312
  201945_at                              furin (paired basic amino acid cleaving enzyme)                         NM_002569      186,14        26,50          361,57          25,35          1,94       0,04325
  222003_s\_at                                     dedicator of cytokinesis 6                                    BE857715       141,94        34,44          273,32           3,82          1,93       0,02743
  200747_s\_at                                 nuclear mitotic apparatus protein 1                               NM_006185      177,05        30,13          342,53           1,12          1,93       0,02273
  218494_s\_at                                          SLC2A4 regulator                                         NM_020062      164,72        22,13          317,53          22,57          1,93       0,01816
  217729_s\_at                                  amino-terminal enhancer of split                                 NM_001130      200,99        28,32          386,1           14,93          1,92       0,02748
  208978_at                                          cysteine-rich protein 2                                      U36190        522,29        187,11        1003,95          51,34          1,92       0,02812
  204355_at                                 DEAH (Asp-Glu-Ala-His) box polypeptide 30                            NM_014966      216,71        19,48          415,91          36,10          1,92       0,0208
  226307_at                  transducer of regulated cAMP response element-binding protein (CREB) 2              AW504757       183,05        15,21          351,43          67,63          1,92       0,03444
  204431_at                     transducin-like enhancer of split 2 (E(sp1) homolog, Drosophila)                 NM_003260      191,78        47,68          368,22          11,00          1,92       0,03922
  223179_at                                        yippee-like 3 (Drosophila)                                    BC005009       131,63        33,05          253,07           4,77          1,92        0,037
  214679_x\_at                 guanine nucleotide binding protein (G protein), alpha 11 (Gq class)               AL110227       191,38        15,11          365,57          52,83          1,91       0,0273
  205740_s\_at                                    hypothetical protein MGC10433                                  NM_024321      140,3         11,74          268,07          12,03          1,91       0,01253
  208110_x\_at               mediator of RNA polymerase II transcription, subunit 25 homolog (yeast)             NM_030973      120,74        11,71          231,04          22,23          1,91       0,01676
  227557_at                                   scavenger receptor class F, member 2                               AI127800       69,68          7,47          133,39           3,34          1,91       0,01744
  203254_s\_at                                               talin 1                                             NM_006289      302,17        24,41          576,14          97,40          1,91       0,02533
  225868_at                                      tripartite motif-containing 47                                  AW249467       260,23        15,67          497,05          68,76          1,91       0,03083
  217912_at                                              PP3111 protein                                          NM_022156      301,95        39,31          573,85          26,94           1,9       0,01004
  219802_at                                       hypothetical protein FLJ22028                                  NM_024854      247,99        16,16          129,67          17,21          −1,91      0,02723
  220553_s\_at                         PRP39 pre-mRNA processing factor 39 homolog (yeast)                       NM_018333      348,68        49,92          182,71           2,12          −1,91      0,03766
  222129_at                                    Chromosome 2 open reading frame 17                                AK026155       475,98        66,26          248,54          70,12          −1,92      0,00982
  209525_at                             Hepatoma-derived growth factor, related protein 3                        BG285017       399,99        13,42          208,81          72,27          −1,92      0,04455
  214101_s\_at                                 Aminopeptidase puromycin sensitive                                BG153399       518,57        14,39          267,18          60,68          −1,94      0,0284
  201694_s\_at                                       early growth response 1                                     NM_001964      912,16        116,79         467,6           123,62         −1,95      0,00691
  1559391_s\_at                 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 5                AI084451       301,03        26,43          154,27          23,44          −1,95      0,03508
  228193_s\_at                                   Response gene to complement 32                                  AI744499       250,61        22,33          127,67          56,97          −1,96      0,04859
  1556019_at                                     hypothetical protein LOC144874                                  BE502765       1173,2        95,58          596,16          173,35         −1,97      0,01607
  230206_at                                        Dedicator of cytokinesis 5                                    AI692645       158,44        36,03          79,79           11,89          −1,99      0,0427
  229397_s\_at                            Glucocorticoid receptor DNA binding factor 1                           AI275597       147,21        12,14          74,15           11,65          −1,99      0,04387
  1555272_at                                     hypothetical protein LOC285927                                  BC044242       618,29        51,90          310,14          155,33         −1,99      0,04207
  229420_at                                   Similar to 60S ribosomal protein L23a                              AI557425       1107,1        154,44         557,27          237,67         −1,99      0,02051
  219375_at                                                  choline                                             NM_006090      433,25        69,86          216,49          13,98           −2        0,02552
  229787_s\_at                          O-linked N-acetylglucosamine (GlcNAc) transferase                        AI742039       407,25        82,20          203,63          53,17           −2        0,01368
  216246_at                                           Ribosomal protein S20                                      AF113008       718,07        204,97         359,53          80,17           −2        0,03995
  1552664_at                                               folliculin                                            NM_144997      315,35        34,67          156,57          10,05          −2,01      0,01331
  1558504_at                                Similar to hypothetical protein LOC284701                            AF086554       161,72        10,90          79,91           27,44          −2,02      0,0256
  235918_x\_at                                             gb:AL559474                                           AL559474       120,53        29,85           59,5            8,65          −2,03      0,0485
  225920_at                                      hypothetical protein LOC148413                                  AW452640       735,04        27,11          362,24          119,58         −2,03      0,0301
  229538_s\_at                           IQ motif containing GTPase activating protein 3                         AW271106       161,6         20,81          79,43           18,07          −2,03      0,01163
  221910_at                                      hypothetical protein LOC221810                                  BF131965       152,28         9,84          74,67           20,84          −2,04      0,03427
  229630_s\_at                                  Wilms tumor 1 associated protein                                 AU147416       1450,7        50,43          712,54          184,74         −2,04      0,01547
  218737_at                               sno, strawberry notch homolog 1 (Drosophila)                           NM_018183      116,38        20,25          56,81            4,58          −2,05      0,04833
  1561481_at                                 Homo sapiens, clone IMAGE:4827393, mRNA                             BC034606       271,34        79,40          131,55          34,12          −2,06      0,04476
  206448_at                                          zinc finger protein 365                                     NM_014951      198,83        24,74          96,55            1,99          −2,06      0,02286
  238002_at                                          golgi phosphoprotein 4                                      BF342391       886,71        127,65         428,76          97,91          −2,07      0,00471
  204863_s\_at                   interleukin 6 signal transducer (gp130, oncostatin M receptor)                  BE856546       135,03        26,71          65,32           18,57          −2,07      0,03394
  243159_x\_at                                              Myosin X                                             AI247495       363,27        42,74          175,08          38,42          −2,07      0,00176
  234344_at                                   RAP2C, member of RAS oncogene family                               AF093744       267,15        21,81          128,37          30,05          −2,08      0,01344
  214038_at                                      chemokine (C-C motif) ligand 8                                  AI984980       168,57        27,35          79,65            5,77          −2,12      0,02801
  242467_at                     Full-length cDNA clone CS0DJ012YP16 of T cells (Jurkat cell line)                BF433200       213,36        47,26          100,12           8,02          −2,13      0,04832
  224346_at                                               gb:AF116671.1                                          AF116671       245,39        57,23          114,94          37,07          −2,13      0,01828
  241872_at                                     Hypothetical protein DKFZp761D221                                AI149963       354,96        59,53          165,78          12,12          −2,14      0,0268
  202425_x\_at     protein phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform (calcineurin A alpha)   NM_000944      837,16         7,08          391,06          61,98          −2,14      0,0101
  235999_at         Heterogeneous nuclear ribonucleoprotein D (AU-rich element RNA binding protein 1, 37 kDa)    AA863112       136,83        22,52          63,56           19,97          −2,15      0,02282
  217550_at                                     Activating transcription factor 6                                AA576497       517,27        117,65         238,89          64,33          −2,17      0,0154
  1565765_x\_at                                   Hypothetical protein FLJ14834                                  AL832478       618,76        41,26          285,03          110,71         −2,17      0,02286
  219138_at                                           ribosomal protein L14                                      BC000606       568,98        102,87         262,25          146,81         −2,17      0,02015
  228545_at                                     Zinc finger protein 148 (pHZ-52)                                 AI016784       166,27        30,20          76,32            7,03          −2,18      0,04509
  239376_at                                   CDNA clone IMAGE:4333081, partial cds                              AA489041       244,11        20,12          111,45          30,03          −2,19      0,04759
  201159_s\_at                                      N-myristoyltransferase 1                                     NM_021079      98,32         10,08           44,9            7,35          −2,19      0,04858
  240145_at              Transcribed locus, moderately similar to NP_008471.1 Canis familiaris ND1 gene          AW628059       118,98        22,05          54,36           14,20          −2,19      0,04816
  238608_at                                              Laminin, beta 1                                         AI174988       301,52        55,25          136,99          40,66          −2,2       0,00821
  244356_at                            Protein tyrosine phosphatase, non-receptor type 12                        AL079909       133,28        14,99          60,41            0,79          −2,21      0,03174
  244757_at                           Cytochrome P450, family 2, subfamily R, polypeptide 1                      AI692525       98,81         17,21          44,57           21,09          −2,22      0,01478
  204296_at                                              gb:NM_021196.1                                          NM_021196      109,35        26,51          49,24            7,95          −2,22      0,04929
  224250_s\_at                                       SECIS binding protein 2                                     BC001189       261,83        60,16          117,72           9,62          −2,22      0,04101
  212952_at                                               Calreticulin                                           AA910371       1511,5        396,05         675,96          133,87         −2,24      0,03178
  243993_at                                         PCTAIRE protein kinase 2                                     AA436887       393,92        77,35          176,13           6,16          −2,24      0,03576
  232118_at                                   Chromosome 20 open reading frame 155                                R33735        298,56         7,84          132,41          47,33          −2,25      0,03847
  202028_s\_at                                            gb:BC000603.1                                          BC000603       2150,5        446,40         939,35          211,88         −2,29      0,01471
  209207_s\_at                      SEC22 vesicle trafficking protein-like 1 (S. cerevisiae)                     BC001364       705,55        75,30          307,12          77,55          −2,3       0,00335
  242560_at                                 Fanconi anemia, complementation group D2                             AA579890       121,37        27,26          52,58           26,19          −2,31      0,04905
  226085_at                            Chromobox homolog 5 (HP1 alpha homolog, Drosophila)                       AA181060       674,11        177,98         288,47          107,20         −2,34      0,0154
  206438_x\_at                                    hypothetical protein FLJ12975                                  NM_024809      488,81        19,84          207,71          74,71          −2,35      0,03745
  1560402_at                                        growth arrest-specific 5                                     BF336936       430,65        47,57          182,35          90,17          −2,36      0,01151
  225116_at                                 Homeodomain interacting protein kinase 2                             AW300045       539,53        90,42          228,41          79,96          −2,36      0,01139
  214395_x\_at       Eukaryotic translation elongation factor 1 delta (guanine nucleotide exchange protein)      AI335509       194,14        37,67          82,06           44,72          −2,37      0,03623
  1558019_at                                                Dystonin                                             BC020911       327,5         63,55          137,33          30,17          −2,38      0,01177
  1564072_at                                              gb:AK025690.1                                          AK025690       1020,1        152,50         428,9           82,66          −2,38      0,03267
  226643_s\_at                                      NudC domain containing 2                                     AI291200       373,57        27,38          156,7           79,47          −2,38      0,02316
  231393_x\_at                                      Zinc finger protein 297B                                     AW237165       158,76        22,10          66,09           26,02          −2,4       0,03737
  231370_at                 Protein phosphatase 1A (formerly 2C), magnesium-dependent, alpha isoform             AI701170       264,16        54,30          108,58          26,09          −2,43      0,01432
  1563283_at                                 Homo sapiens, clone IMAGE:4828909, mRNA                             BG718722       843,46        98,58          345,82          109,30         −2,44      0,00876
  213426_s\_at                                             caveolin 2                                            AA150110       470,58        114,98         189,36          102,20         −2,49      0,0063
  213734_at                                    WD repeat and SOCS box-containing 2                               BG260658       740,32        176,82         296,21          80,29          −2,5       0,01662
  229165_at                                    Mitochondrial ribosomal protein L12                               BF433010       162,11        10,83          64,37           23,71          −2,52      0,03196
  202648_at                                           ribosomal protein S19                                      BC000023       529,75        51,94          209,85          38,50          −2,52      0,00463
  220839_at                                         methyltransferase like 5                                     NM_014168      237,93        77,58          93,29           36,86          −2,55      0,04023
  242485_at                                      PTK2 protein tyrosine kinase 2                                  AW178807       166,68        31,29          64,65           10,50          −2,58      0,0348
  230820_at                                SMAD specific E3 ubiquitin protein ligase 2                           BF111169       1460,4        212,19         549,25          150,26         −2,66      0,00218
  222027_at                  Nuclear ubiquitous casein kinase and cyclin-dependent kinase substrate              AW515443       111,81         7,14          41,65           10,47          −2,68      0,03024
  212649_at                                               gb:AL079292.1                                          AL079292       202,52        44,29          75,22           39,30          −2,69      0,02723
  228477_at                                       Hypothetical protein FLJ10154                                   R53084        1465,2        151,71         541,96          142,16         −2,7       0,00166
  239859_x\_at            ATP synthase, H+ transporting, mitochondrial F0 complex, subunit s (factor B)          AW140122       93,77          4,18          33,72           15,53          −2,78      0,04668
  210758_at                                    PC4 and SFRS1 interacting protein 1                               AF098482       444,61        36,70          156,69          37,48          −2,84      0,02343
  1557830_at                                                Cyclin J                                             AW063658       367,31        19,61          126,36          23,00          −2,91      0,00916
  1559521_at                           MRNA full length insert cDNA clone EUROIMAGE 29093                        AL355741       258,03        21,91          84,38           45,58          −3,06      0,02554
  200908_s\_at                                     ribosomal protein, large P2                                   BC005354       575,68        24,55          187,15          108,90         −3,08      0,02087
  224375_at                                               gb:AF271776.1                                          AF271776       795,28        79,08          248,14          145,83         −3,2       0,01506
  233204_at                                       Hypothetical protein MGC40405                                  AA115105       107,54        17,25          30,82           10,88          −3,49      0,02822
  230084_at                           solute carrier family 30 (zinc transporter), member 2                      BF510698       814,56        203,67         232,49          146,26         −3,5       0,01187
  232351_at                                   CDNA FLJ12246 fis, clone MAMMA1001343                              AK022308       158,29        39,36          45,15           10,32          −3,51      0,03121
  243885_x\_at                                               Latexin                                             AA526937       92,06         29,95          26,17           11,58          −3,52      0,03092
  241617_x\_at                                             gb:BE961949                                           BE961949       93,34         23,47          25,35           11,78          −3,68      0,02206
  214313_s\_at                             Eukaryotic translation initiation factor 5B                           BE138647       113,14        16,37          29,69           14,69          −3,81      0,02274
  1553749_at                                      hypothetical protein MGC33371                                  NM_144664      194,53        71,06           50,5           27,11          −3,85      0,04744
  1553575_at                                             gb:NM_173714.1                                          NM_173714      440,06        81,16          108,49          27,98          −4,06      0,01314
  220787_at                                              gb:NM_018629.1                                          NM_018629      72,95          6,02          17,61            5,48          −4,14      0,01972
  213813_x\_at                                             gb:AI345238                                           AI345238       232,05        35,44            55            23,58          −4,22      0,00713
  233047_at                                       hypothetical protein LOC90167                                  AL161984       451,93        128,65          84,7           14,81          −5,34      0,03067

Comparison of Gene Expression Profiles by Hierarchical Clusters and Principal Component Analysis (PCA) {#s3b}
------------------------------------------------------------------------------------------------------

Hierarchical Clusters were used to analyze the expression profile of the different samples ([Figure 1](#pone-0008242-g001){ref-type="fig"}). Results identified broad similarities among arrays hybridized with the mRNA of control cells or among arrays hybridized with mRNA of cells treated with estradiol. Even though the overall signal patterns found on the mRNA hybridized arrays were similar, a small subset of regions show differential expression signals between the mRNA of control cells and mRNA of cells treated with estradiol.

![Supervised hierarchical cluster of HUVEC gene expression changes in response to estradiol.\
263 probe sets of genes significantly regulated by greater than 1.8-fold change were used for 2D hierarchical clustering. Each row represents an individual probe set, and each column represents a pool of cells (C1, C2 and C3: control samples; E1, E2 and E3: estradiol-treated samples). 129 up- (red) *or* 134 down- (green) were regulated (P value\<0.05).](pone.0008242.g001){#pone-0008242-g001}

PCA was applied to establish the interrelationships among the samples used in our study. By visualizing projections of these components in low-dimensional spaces, samples were grouped, reflecting underlying patterns in their gene expression profiles. [Figure 2](#pone-0008242-g002){ref-type="fig"} depicts the PCA with the six pools clearly separated into two sets, one set with three control samples, and the other set with three estradiol-treated samples.

![Supervised principal component analysis (PCA).\
Microarray hybridizations were performed using total RNA from HUVEC exposed to 1 nmol/L estradiol for 24 h. The gene expression profiles of 3 pools of control cells (blue) and 3 pools of cells treated with estradiol 1 nmol/L (red) were compared using PCA. The three-dimensional (3D) plot view of gene expression data (including all probe sets on U133 Plus 2.0 GeneChip) is shown, with respect to their correlation to the first three principal components.](pone.0008242.g002){#pone-0008242-g002}

Functional Categorization of Genes {#s3c}
----------------------------------

HUVEC genes regulated by estradiol were organized by function to better understand their profile. This classification showed that estradiol regulated a great number of genes mainly associated with biological processes that include Cellular Growth and Proliferation; Cell-to-cell Signaling; Cellular Assembly and Organization; Cellular Compromise; Cellular Movement and Cell Death, as shown in [Table 3](#pone-0008242-t003){ref-type="table"} (online supporting information). The Cardiovascular System Development and Function also appears as one of the main regulated. Genes with a role in Lipid and Carbohydrate Metabolism, Cell Signaling, Endocrine System Disorders or Metabolic Disease appear to be significantly regulated by estrogens as well. Among these biological processes, the greater part of molecules induced by estradiol in HUVEC is related to growth of cells (47 molecules), cell death (47 molecules) and apoptosis (39 molecules), cell movement (32 molecules), growth of eukaryotic cells (25 molecules) adhesion cells (22 molecules), colony formation (16 molecules), development of blood vessels (15 molecules), cell surface receptor linked signal transduction (14 molecules) and angiogenesis (10 molecules).

10.1371/journal.pone.0008242.t003

###### Functional analysis of differentially expressed genes in estradiol-treated HUVEC.

![](pone.0008242.t003){#pone-0008242-t003-3}

  Category                                                                      Process Annotation                    Significance   Molecules
  ----------------------------------------------------------- ------------------------------------------------------ -------------- -----------
  **Cellular Growth and Proliferation**                                          growth of cells                         0,0000         47
                                                                           growth of kidney cell lines                   0,0102          4
                                                                        growth of fibrosarcoma cell lines                0,0103          2
                                                                            growth of eukaryotic cells                   0,0111         25
                                                                      arrest in growth of pre-B lymphocytes              0,0143          1
                                                                            growth of colon cell lines                   0,0143          1
                                                                          growth of hepatoma cell lines                  0,0147          3
                                                                               growth of cell lines                      0,0156         20
                                                                          growth of embryonic cell lines                 0,0158          3
                                                                          growth of lymphoma cell lines                  0,0170          3
                                                                             growth of melanoma cells                    0,0215          2
                                                                          growth of leukemia cell lines                  0,0218          4
                                                                            arrest in growth of cells                    0,0266          6
                                                                                 colony formation                        0,0002         16
                                                                            colony formation of cells                    0,0002         16
                                                                       colony formation of eukaryotic cells              0,0003         15
                                                                       colony formation of tumor cell lines              0,0004         10
                                                                     colony formation of carcinoma cell lines            0,0020          3
                                                                          colony formation of cell lines                 0,0020         11
                                                                       colony formation of red blood cells               0,0059          3
                                                                         colony formation of blood cells                 0,0062          5
                                                                    colony formation of lung cancer cell lines           0,0073          3
                                                                    colony formation of bone cancer cell lines           0,0086          2
                                                                     colony formation of leukemia cell lines             0,0086          2
                                                                   colony formation of connective tissue cells           0,0098          3
                                                                       colony formation of erythroid cells               0,0103          2
                                                                        colony formation of stromal cells                0,0143          1
                                                                     colony formation of erythroid cell lines            0,0144          2
                                                                      colony formation of bone marrow cells              0,0149          4
                                                                    colony formation of lymphatic system cells           0,0165          4
                                                                        colony formation of myeloid cells                0,0251          3
                                                                  colony formation of prostate cancer cell lines         0,0270          2
                                                                        proliferation of endothelial cells               0,0015          7
                                                                arrest in proliferation of bone cancer cell lines        0,0143          1
                                                                          proliferation of granulocytes                  0,0215          2
                                                                        formation of osteoclast-like cells               0,0123          2
                                                                        formation of epithelial cell lines               0,0143          1
                                                                       formation of lung cancer cell lines               0,0143          1
                                                                             formation of macrophages                    0,0215          2
                                                                             formation of blood cells                    0,0266          3
                                                                          induction of mesenchymal cells                 0,0143          1
                                                                       inhibition of endothelial cell lines              0,0143          1
                                                                         inhibition of endothelial cells                 0,0143          1
                                                                     inhibition of ovarian cancer cell lines             0,0143          1
                                                                        inhibition of smooth muscle cells                0,0143          1
                                                                         stimulation of progenitor cells                 0,0143          1
                                                                       suppression of fibroblast cell lines              0,0143          1
                                                                          suppression of lung cell lines                 0,0143          1
                                                                   expansion of hematopoietic progenitor cells           0,0190          2
  **Cell-To-Cell Signaling and Interaction**                                  binding of stem cells                      0,0002          2
                                                                           binding of female germ cells                  0,0054          2
                                                                         binding of embryonic stem cells                 0,0143          1
                                                                          binding of stromal cell lines                  0,0143          1
                                                                                 binding of sperm                        0,0242          2
                                                                                adhesion of cells                        0,0012         22
                                                                           adhesion of tumor cell lines                  0,0176          7
                                                                      attachment of brain cancer cell lines              0,0020          2
                                                                          attachment of tumor cell lines                 0,0073          3
                                                                       attachment of intestinal cell lines               0,0143          1
                                                                             attachment of spermatids                    0,0143          1
                                                                           attachment of spermatocytes                   0,0143          1
                                                                             attachment of cell lines                    0,0170          3
                                                                          attachment of eukaryotic cells                 0,0280          4
                                                                         accumulation of focal adhesions                 0,0143          1
                                                                        activation of carcinoma cell lines               0,0143          1
                                                               contact growth inhibition of fibrosarcoma cell lines      0,0143          1
                                                                        development of intercalated disks                0,0143          1
                                                                        disassembly of adherens junctions                0,0143          1
                                                                          induction of mesenchymal cells                 0,0143          1
                                                                          maintenance of focal adhesions                 0,0143          1
                                                                       production of cell-associated matrix              0,0143          1
                                                                       response of breast cancer cell lines              0,0143          1
                                                                      sensitization of leukocyte cell lines              0,0143          1
                                                                         stimulation of progenitor cells                 0,0143          1
                                                                       suppression of fibroblast cell lines              0,0143          1
                                                                          suppression of lung cell lines                 0,0143          1
  **Cellular Compromise**                                                   fragmentation of vesicles                    0,0002          2
                                                                           fragmentation of hepatocytes                  0,0143          1
                                                                         degeneration of epithelial cells                0,0012          2
                                                                              degeneration of cells                      0,0061          6
                                                                          degeneration of keratinocytes                  0,0143          1
                                                                  degeneration of renal tubular epithelial cells         0,0143          1
                                                                                shrinkage of cells                       0,0086          2
                                                                              depletion of podocytes                     0,0143          1
                                                                        disassembly of adherens junctions                0,0143          1
                                                                         disruption of PML nuclear bodies                0,0143          1
                                                                            disruption of spindle pole                   0,0143          1
  **Cardiovascular System Development and Function**                      development of vascular tissue                 0,0002          3
                                                                           development of blood vessel                   0,0005         15
                                                                        proliferation of endothelial cells               0,0015          7
                                                                       cell flattening of endothelial cells              0,0143          1
                                                                          concentration of blood vessel                  0,0143          1
                                                                       inhibition of endothelial cell lines              0,0143          1
                                                                         inhibition of endothelial cells                 0,0143          1
                                                                            length of endothelial tube                   0,0143          1
                                                                           migration of cardiomyocytes                   0,0143          1
                                                                       muscularization of pulmonary artery               0,0143          1
                                                                      thickness of right ventricle of heart              0,0143          1
                                                                                   angiogenesis                          0,0182         10
                                                                              angiogenesis of tumor                      0,0251          3
                                                                                  vasculogenesis                         0,0236          3
  **Carbohydrate Metabolism**                                             modification of polysaccharide                 0,0002          4
                                                                             modification of N-glycan                    0,0003          3
                                                                           modification of carbohydrate                  0,0181          4
                                                                        metabolism of glucose-6-phosphate                0,0012          2
                                                                       moiety attachment of polysaccharide               0,0041          2
                                                                        moiety attachment of carbohydrate                0,0166          2
                                                                              processing of N-glycan                     0,0069          2
                                                                           galactosylation of N-glycan                   0,0143          1
                                                                        utilization of glucose-6-phosphate               0,0143          1
  **Skeletal and Muscular System Development and Function**                    area of muscle cells                      0,0006          3
                                                                        formation of osteoclast-like cells               0,0123          2
                                                                        development of intercalated disks                0,0143          1
                                                                           development of tracheal ring                  0,0143          1
                                                                        inhibition of smooth muscle cells                0,0143          1
                                                                                length of skeleton                       0,0143          1
                                                                           migration of cardiomyocytes                   0,0143          1
                                                                          morphology of skeletal muscle                  0,0143          1
                                                                       muscularization of pulmonary artery               0,0143          1
                                                                             size of medullary cavity                    0,0143          1
                                                                              myogenesis of organism                     0,0215          2
                                                                        differentiation of bone cell lines               0,0280          4
  **Cellular Assembly and Organization**                                 accumulation of actin filaments                 0,0012          2
                                                                            accumulation of filaments                    0,0054          2
                                                                         accumulation of focal adhesions                 0,0143          1
                                                                               assembly of vesicles                      0,0030          2
                                                                           assembly of actin filaments                   0,0090          4
                                                                         cross-linkage of actin filaments                0,0030          2
                                                                         cross-linkage of microfilaments                 0,0143          1
                                                                         biogenesis of actin cytoskeleton                0,0065          5
                                                                            biogenesis of mitochondria                   0,0144          2
                                                                            biogenesis of cytoskeleton                   0,0167          6
                                                                        association of actin cytoskeleton                0,0143          1
                                                                          deposition of collagen fibrils                 0,0143          1
                                                                      deposition of reticulin fiber networks             0,0143          1
                                                                          detachment of desmin filament                  0,0143          1
                                                                        development of intercalated disks                0,0143          1
                                                                           development of mitochondria                   0,0190          2
                                                                         disruption of PML nuclear bodies                0,0143          1
                                                                            disruption of spindle pole                   0,0143          1
                                                                        immobilization of actin filaments                0,0143          1
                                                                        maturation of olfactory glomeruli                0,0143          1
                                                                           organization of cell cortex                   0,0143          1
                                                                           organization of microtubules                  0,0242          2
                                                                      polymerization of actin stress fibers              0,0143          1
                                                                       production of cell-associated matrix              0,0143          1
                                                                     quantity of mitochondrial contact sites             0,0143          1
                                                                        quantity of multivesicular bodies                0,0143          1
                                                                           formation of actin filaments                  0,0145          7
                                                                              formation of filaments                     0,0254          8
                                                                                formation of axons                       0,0270          2
                                                                            stabilization of filaments                   0,0251          3
                                                                             reorganization of actin                     0,0270          2
  **Cellular Movement**                                                     chemotaxis of lymphocytes                    0,0025          6
                                                                       chemotaxis of mononuclear leukocytes              0,0030          7
                                                                        chemotaxis of natural killer cells               0,0042          3
                                                                           chemotaxis of T lymphocytes                   0,0134          4
                                                                             chemotaxis of leukocytes                    0,0227          7
                                                                            chemotaxis of blood cells                    0,0275          7
                                                                         migration of dermal fibroblasts                 0,0030          2
                                                                          migration of trophoblast cells                 0,0054          2
                                                                           migration of embryonic cells                  0,0127          4
                                                                           migration of cardiomyocytes                   0,0143          1
                                                                          migration of endodermal cells                  0,0143          1
                                                                              homing of lymphocytes                      0,0041          6
                                                                         homing of mononuclear leukocytes                0,0045          7
                                                                             homing of T lymphocytes                     0,0165          4
                                                                                  cell movement                          0,0048         32
                                                                       cell movement of dermal fibroblasts               0,0069          2
                                                                      cell movement of natural killer cells              0,0098          3
                                                                         cell movement of embryonic cells                0,0141          4
                                                                           cell movement of lymphocytes                  0,0147          8
                                                                     cell movement of mononuclear leukocytes             0,0177          9
                                                                                 release of cells                        0,0086          2
                                                                       infiltration of hairy leukemia cells              0,0143          1
                                                                            locomotion of neutrophils                    0,0143          1
                                                                      scattering of pancreatic cancer cells              0,0143          1
                                                                      scattering of squamous carcinoma cells             0,0143          1
                                                                           translocation of spermatids                   0,0143          1
                                                                          haptotaxis of tumor cell lines                 0,0144          2
  **Cell Death**                                                       cell death of fibroblast cell lines               0,0002         13
                                                                             cell death of cell lines                    0,0019         32
                                                                         cell death of kidney cell lines                 0,0019          9
                                                                        cell death of prostate cell lines                0,0041          2
                                                                          cell death of eukaryotic cells                 0,0051         40
                                                                                    cell death                           0,0052         47
                                                                        cell death of embryonic cell lines               0,0067          7
                                                                      cell death of neuroblastoma cell lines             0,0109          5
                                                                           cell death of thyroid cells                   0,0123          2
                                                                            cell death of muscle cells                   0,0133          6
                                                                       cell death of endothelial cell lines              0,0165          4
                                                                       cell death of epithelial cell lines               0,0185          7
                                                                        delay in cell death of cell lines                0,0190          2
                                                                            cell death of eosinophils                    0,0215          2
                                                                     cell death of nervous tissue cell lines             0,0266          3
                                                                            cell death of splenocytes                    0,0270          2
                                                                           regeneration of blood cells                   0,0012          2
                                                                         regeneration of blood platelets                 0,0143          1
                                                                  regeneration of hematopoietic progenitor cells         0,0143          1
                                                                         regeneration of red blood cells                 0,0143          1
                                                                          apoptosis of kidney cell lines                 0,0014          8
                                                                         apoptosis of prostate cell lines                0,0020          2
                                                                        apoptosis of embryonic cell lines                0,0066          6
                                                                      delay in apoptosis of tumor cell lines             0,0103          2
                                                                            apoptosis of thyroid cells                   0,0123          2
                                                                        apoptosis of fibroblast cell lines               0,0123          8
                                                               apoptosis of granulocyte-macrophage progenitor cells      0,0143          1
                                                                             apoptosis of liver cells                    0,0157          4
                                                                         delay in apoptosis of cell lines                0,0190          2
                                                                        apoptosis of epithelial cell lines               0,0195          6
                                                                                    apoptosis                            0,0200         39
                                                                             apoptosis of eosinophils                    0,0215          2
                                                                             apoptosis of splenocytes                    0,0215          2
                                                                            apoptosis of muscle cells                    0,0227          5
                                                                          apoptosis of hippocampal cells                 0,0242          2
                                                                        apoptosis of cerebral cortex cells               0,0266          3
                                                                      apoptosis of stomach cancer cell lines             0,0270          2
                                                                       colony survival of eukaryotic cells               0,0047          3
                                                                                 colony survival                         0,0059          3
                                                                             colony survival of cells                    0,0059          3
                                                                      colony survival of lymphoma cell lines             0,0143          1
                                                                    cell viability of neuroblastoma cell lines           0,0086          2
                                                                           survival of endocrine cells                   0,0103          2
                                                                              survival of germ cells                     0,0123          2
                                                                            survival of gonadal cells                    0,0144          2
                                                                     survival of pheochromocytoma cell lines             0,0242          2
                                                                         survival of hematopoietic cells                 0,0270          2
  **Lipid Metabolism**                                                 biosynthesis of phosphatidylinositol              0,0041          2
                                                                        biosynthesis of phosphatidic acid                0,0042          3
                                                                           biosynthesis of phospholipid                  0,0116          3
                                                                  biosynthesis of dolichol monophosphate mannose         0,0143          1
                                                                   binding of 1-alpha, 25-dihydroxy vitamin D3           0,0143          1
                                                                              formation of 5(S)-HETE                     0,0143          1
                                                                       production of 25-hydroxy-vitamin D3               0,0143          1
                                                                          production of cholecalciferol                  0,0143          1
                                                                              reduction of ceramide                      0,0143          1
                                                                          utilization of triacylglycerol                 0,0143          1
  **Cardiovascular Disease**                                                 hypoplasia of myocardium                    0,0054          2
                                                                            fibrosis of portal artery                    0,0143          1
                                                                       muscular dystrophy of cardiac muscle              0,0143          1
                                                                           tetralogy of Fallot of mice                   0,0143          1
                                                                       cell death of endothelial cell lines              0,0165          4
                                                                         cardiovascular disorder of heart                0,0195          3
  **Cell Signaling**                                             cell surface receptor linked signal transduction        0,0063         14
                                                                           suppression of nitric oxide                   0,0143          1
                                                                       androgen receptor signaling pathway               0,0166          2
  **Metabolic Disease**                                                            amyloidosis                           0,0106          3
                                                                      familial partial lipodystrophy type 2              0,0143          1
                                                                        pseudohypoparathyroidism, type 1B                0,0143          1
  **Endocrine System Disorders**                                            apoptosis of thyroid cells                   0,0123          2
                                                                           cell death of thyroid cells                   0,0123          2
                                                                    differentiation of pancreatic cancer cells           0,0143          1
                                                                             McCune-Albright syndrome                    0,0143          1
                                                                        pseudohypoparathyroidism, type 1B                0,0143          1
                                                                      scattering of pancreatic cancer cells              0,0143          1
                                                                    spontaneous autoimmune thyroiditis of mice           0,0143          1
                                                                     survival of pheochromocytoma cell lines             0,0242          2
  **Free Radical Scavenging**                                         production of reactive oxygen species              0,0243          5

The functional characterization of data are presented in [Figure 3](#pone-0008242-g003){ref-type="fig"}, which lists top ten canonical pathways regulated by estrogen across both tissue types. The top five canonical pathways based on their significance (P value) included Notch Signaling, Actin Cytoskeleton Signaling, Pentose Phosphate Pathway, Axonal Guidance Signaling and Integrin Signaling. Genes included in each group of the top ten signaling pathways presented in [Figure 3](#pone-0008242-g003){ref-type="fig"} are listed in [Table 4](#pone-0008242-t004){ref-type="table"}.

![Top ten signaling and metabolic pathways regulated by estradiol.\
For the functional categorization of genes, Fischer\'s exact test was used to calculate a p value (shown as bars) determining the probability that each biological function assigned to the network is due to chance alone. The ratio (shown as squares) represents the number of differentially expressed genes in a given pathway divided by total number of genes that make up that canonical pathway.](pone.0008242.g003){#pone-0008242-g003}

10.1371/journal.pone.0008242.t004

###### Significant genes included in the top ten canonical pathways presented in [Figure 3](#pone-0008242-g003){ref-type="fig"}.

![](pone.0008242.t004){#pone-0008242-t004-4}

  Cannonical pathway                         Significant genes included in each group of the top ten canonical pathways
  --------------------------------- --------------------------------------------------------------------------------------------
  Notch signaling                                                    FURIN, JAG2, NOTCH4, RFNG
  Actin cytoskeleton signaling       ACTN4, ARHGEF1, ARHGEF12,GRLF1, GSN, IQGAP3,MAPK3, MYH16, MYL9, PAK4, PDGFA, PIP5K1C, RAC2
  Pentose phosphate pathway                                         G6PD, GPI, PFKL, PGLS, PRPS2
  Axonal guidance signaling          ADAM15, AKT1, ARHGEF12, GNA11, GNB2, MAPK3, MYL9,PAK4, PDGFA, PLXNB2, PPP3CA, RAC2, SEMA6B
  Integrin signaling                            ACTN4, AKT1, ARF3, ARF6, ITGA5, MAPK3, PAK4, PARVB, RAC2, RHOC, TNK2
  Galactose metabolism                                                   GALT, UGALT, UGT2
  VEGF signaling                                                      ARNT, PI3K, ACTC, BCL-XL
  Huntington\'s disease signaling            AKT1, ARFIP2, CTSD, DCTN1, GNA11, GNB2, HDAC7A, POLR2L, SNCA, TGM2, UBE2S
  N-glycan biosynthesis                                            B4GALT5, DPM3, MAN1B1, MGAT4B
  Inositol phosphate metabolism                                           IP3K, PI4K, PI3K

When the IPA software was used to analyze the probe sets there were 26 significant regulatory networks (score\>2), of which 5 were highly significant (score\>20). The number one ranked network (score = 62, focus molecules = 33) ([Figure 4](#pone-0008242-g004){ref-type="fig"}) is associated with Cardiovascular System Development and Function, Cellular Growth and Proliferation and Cell Morphology. Transforming Growth Factor beta-1 (TGFB1) plays a central role in the formation of this network. Top functions of the other four highly significant networks are associated with Cellular Compromise, Cellular Movement, Hematological System Development and Function, Lipid Metabolism, Molecular Transport and Small Molecule Biochemistry.

![The most significant network regulated by estradiol is centered on TGFB1.\
Networks of genes were algorithmically generated with the IPA software based on their connectivity and assigned a score. The intensity of the node color indicates the degree of up- (red) or down- (green) regulation. A continuous line means a direct relationship between the two genes, whereas a discontinuous line indicates an indirect association. The most significant network regulated by estradiol includes 33 genes with an assigned score of 62 and is centered on TGFB1.](pone.0008242.g004){#pone-0008242-g004}

Microarray Analysis Verification {#s3d}
--------------------------------

To validate the HUVEC gene expression changes induced by estradiol in the microarray analysis, QRT-PCR was performed in a separate series of follow-up studies of HUVEC exposed to different concentrations (0,01--100 nmol/L) of estradiol. Target genes were selected based upon their important cardiovascular functions and were genes encoding for DDAH1, DDAH2, PLA2G4A, PLA2G4B, COX1, COX2 and DHCR7.

Estradiol dose-dependent increased mRNA expression of COX1, DDAH2, PLA2G4B, and DHCR7 ([Figure 5](#pone-0008242-g005){ref-type="fig"}). In all cases, the effect afforded by 1 nmol/L estradiol was significantly higher than that of 0,01 nmol/L estradiol. There were no differences between the effects on gene expression induced by the higher tested concentrations (1, 10 and 100 nmol/L), although in the case of DHCR7 the effect of 10 nmol/L was 34% higher than that of 1 nmol/l. The increased gene expressions induced by 1 nmol/L estradiol were similar to change levels obtained in the microarray analysis (probeset 205128_x\_at for COX1, - fold change of 1.56 -p = 0.007-, probeset 202262_x\_at for DDAH2 -fold change: 1.37, p = 0.045-, probeset 219095_at for PLA2G4B -fold change 1.56, p = 0.019-, and probeset 201790_s\_at for DHCR7 -fold change 1.79, p = 0.005-).

![QRT-PCR confirms some estradiol up-regulated selected genes from the microarray analysis.\
HUVEC were exposed to different estradiol concentrations (0,01--100 nmol/L), and to 1 µmol/L ICI182780 alone or plus 1 nmol/L estradiol, and the relative expression of the genes was quantified: (A) COX1, (B) DDAH2, (C) PLA2G4B, and (D) DHCR7. Data are percentage of control values and are mean ± SEM of 5--19 values (4--6 different experiments). \* p\<0.05, \*\* p\<0.01 or \*\*\* p\<0.001 vs. control cells, † p\<0.05 vs. 0.01 nmol/L estradiol, and ‡ p\<0.05 vs. 1 nmol/L estradiol.](pone.0008242.g005){#pone-0008242-g005}

The mRNA expression of COX2, DDAH1 and PLA2G4A ([Figure 6](#pone-0008242-g006){ref-type="fig"}) remained unaltered under all the estradiol concentrations, as in the microarray analysis (probeset 204748_at for COX2 -fold change: −1.18, p = 0.541-, probeset 209094_at for DDAH1-fold change: −1.03, p = 0.743-, and probeset 210145_at for PLA2G4A -fold change −1.06, p = 0.570-).

![Unregulated genes in microarray analysis were also unchanged by QRT-PCR.\
HUVEC were exposed to different estradiol concentrations (0,01--100 nmol/L), and to 1 µmol/L ICI182780 alone or plus 1 nmol/L estradiol, for 24 hours. Total cellular RNA was extracted, and the relative expression of the genes was quantified using specific primers for (A) COX2, (B) DDAH1 and (C) PLA2G4A. The GADPH gene was used as control as described in [Materials and Methods](#s2){ref-type="sec"}. Data are expressed as percentage of control values and are mean ± SEM of 5--17 values corresponding to 5 different experiments.](pone.0008242.g006){#pone-0008242-g006}

Estradiol genomic effects are mainly mediated through ERα and ERβ. HUVEC express both types of ER ([Figure 7](#pone-0008242-g007){ref-type="fig"}), and no changes in protein expression of both types of ER were observed after exposure to estradiol, ICI 182780, or estradiol plus ICI182780 ([Figure 7](#pone-0008242-g007){ref-type="fig"}). To study the role of ER on the effects induced by estradiol on gene expression, cells were exposed to the nonselective ER antagonist ICI182780. In cells exposed to different concentrations (0,01 -- 10 µmol/L) of ICI 182780 alone, expression of the seven selected genes remained unaltered ([Table 5](#pone-0008242-t005){ref-type="table"}), thus discarding a direct effect of ICI 182780 on gene profile. In cells coexposed to 1 nmol/L estradiol plus 1 µmol/L ICI182780 for 24 h, estradiol-induced effects on gene expression were completely abolished ([Figure 5](#pone-0008242-g005){ref-type="fig"}).

![Estrogen receptor alpha and beta protein expression in HUVEC.\
Cells were exposed to 1 nmol/L estradiol with or without 1 µmol/L ICI182780 for 24 hours, and protein expression of (A) ERα and (B) ERβ were measured as stated in [Materials and methods](#s2){ref-type="sec"}. A typical immunoblotting image and relative levels assessed by densitometry of bands of 66-kDa (ERα) or 56-kDa (ERβ) are presented. Data are percentage of control values and are mean ± SEM of 6 values (3 different experiments).](pone.0008242.g007){#pone-0008242-g007}

10.1371/journal.pone.0008242.t005

###### Expression of selected genes from the microarray under different ICI 182780 concentrations.

![](pone.0008242.t005){#pone-0008242-t005-5}

  ICI 182780 (µmol/L)    Gene expresión (% of control values)                                              
  --------------------- -------------------------------------- -------- -------- -------- -------- ------- --------
  0,01                                   96±9                   102±3     95±8     99±6    104±11   99±10    98±4
  0,1                                   110±9                   102±11    95±7    100±7    101±7    96±9    102±7
  1                                      95±8                   108±12   108±8    106±7    107±6    101±9   105±10
  10                                    101±10                  101±7    105±12   106±11   100±3    98±16   102±9

Data are expressed as percentage of control values and are mean±SEM of 4--7 values corresponding to 2 different experiments.

To further validate microarray data, COX1 and COX2 protein expression were analyzed by immunoblotting ([Figure 8A and 8B](#pone-0008242-g008){ref-type="fig"}). Estradiol increased COX1 protein expression up to 30 % of control values, whereas COX2 protein expression remained unchanged, in sharp agreement to data obtained from microarray analysis and QRT-PCR assays. Moreover, estradiol-induced COX1 up-regulation resulted in an increased production of prostacyclin, the main vasodilatory prostanoid regulated by COX activity ([Figure 8C](#pone-0008242-g008){ref-type="fig"}). These stimulatory effects of estradiol on prostacyclin synthesis pathway were mediated through ER activation, since were abolished in the presence of ICI 182780.

![Estradiol up-regulated COX1 protein expression results in increased prostacyclin production through ER.\
HUVEC were exposed to 1 nmol/L estradiol with or without 1 µmol/L ICI182780, and protein expression of (A) COX1 and (B) COX2 and prostacyclin production (C) were measured as stated in [Materials and methods](#s2){ref-type="sec"}. Data are percentage of control values and are mean ± SEM of 6--8 values (3--4 different experiments). \* p\<0.05 or \*\* p\<0.01 vs. control cells, and † p\<0.05 vs. estradiol-alone treated cells.](pone.0008242.g008){#pone-0008242-g008}

In a similar way, estradiol-induced changes in the DDAH gene expression were correlated to similar changes in protein expression. DDAH2 protein expression was increased in the presence of estradiol, whereas DDAH1 remained unchanged ([Figure 9A and 9B](#pone-0008242-g009){ref-type="fig"}). *In vivo*, DDAH degrades most of ADMA [@pone.0008242-Vallance1], an endogenous inhibitor of NO synthase. The increased DDAH expression resulted in decreased ADMA production ([Figure 9C](#pone-0008242-g009){ref-type="fig"}), which in turn lead to an increased NO production after estradiol exposure ([Figure 9D](#pone-0008242-g009){ref-type="fig"}). The effects of estradiol on the DDAH-ADMA-NO pathways were mediated by ER, since were abolished in the presence of ICI 182780.

![Estradiol up-regulated DDAH2 protein expression results in decreased ADMA production and increased NO release mediated by ER.\
HUVEC were exposed to 1 nmol/L estradiol with or without 1 µmol/L ICI182780, and protein expression of (A) DDAH1 and (B) DDAH2, along with (C) ADMA levels and NO production, were measured as stated in [Materials and methods](#s2){ref-type="sec"}. Data are percentage of control values and are mean ± SEM of 9--12 values (4 different experiments). \* p\<0.05 or \*\* p\<0.01 vs. control cells, and † p\<0.05 vs. estradiol-alone treated cells.](pone.0008242.g009){#pone-0008242-g009}

Discussion {#s4}
==========

This study summarizes changes in complete gene expression in human endothelial cells exposed to estradiol. We have identified new genes that are up-regulated in endothelium by exposure to a physiological concentration of estradiol (1 nmol/L) for 24 hours, a time and a concentration selected according to previous work of our group [@pone.0008242-Monsalve1]. We have identified 1886 genes differentially expressed. Taking advantage of ranked gene expression pathways, results have shown that pathways related to cellular growth and proliferation, cell-to-cell signaling and cellular organization, movement and death were among the most differentially expressed.

Canonical pathway analysis revealed Notch signaling as the most significant signaling pathway modulated by estradiol. Aberrant Notch signaling is implicated in carcinogenesis and tumor angiogenesis [@pone.0008242-Leong1], and interestingly with human pathologies involving cardiovascular abnormalities [@pone.0008242-Uyttendaele1]. Recently, it was reported that Notch pathway regulates cell-cell or cell-matrix interaction, contributing hence, to cell migration in situations of tissue remodeling [@pone.0008242-Lindner1]. Also, Notch1 has been implicated in the estradiol-induced increase in microvessel density *in vivo* and therefore in estradiol-increased tumor angiogenesis in MCF7 cells and HUVEC [@pone.0008242-Soares1]. Our findings provide further support for the important role that Notch signaling pathway plays on endothelial effects of estradiol.

Estradiol has also important effects on other signaling pathways, mainly in Actin Cytoskeleton Signaling, Integrin Signaling, and Vascular Endothelial Growth Factor (VEGF) Signaling. These pathways exert important vascular actions, such as maintaining vascular integrity, regulating cell cycle, and promoting vasculogenesis. Moreover, four metabolic pathways are among the first 10 pathways significantly modulated by estradiol: Pentose Phosphate Pathway, Galactose Metabolism, N-Glycan Biosynthesis and Inositol Phosphate Metabolism. Some of these effects of estradiol have already been described. Estradiol, for instance, has already reported to increase HUVEC attachment to extracellular matrix proteins, mainly up-regulating surface expression of β1, α5 and α6 integrins [@pone.0008242-Cid1]. Estradiol directly regulates the glucose-6-phosphate dehydrogenase (G6PDH) expression [@pone.0008242-Thomas1], the enzyme that directs glucose carbons into the pentose phosphate pathway. Moreover, estradiol-stimulated breast cancer cells have also increased pentose phosphate pathway activity, suggesting that this pathway is essential for estrogen-dependent cell proliferation [@pone.0008242-Forbes1]. Nevertheless, the majority of genes affected by estradiol treatment have been described for the first time in our results and our data open new approaches to discover unexplored estrogen-regulated pathways and new vascular actions.

The IPA software outlined the most changed pathways in the microarray data. Among them, TGFB1 plays a central role in the formation of the number-one-ranked network, which contains 33 genes ([Figure 4](#pone-0008242-g004){ref-type="fig"}) and is associated with other important cardiovascular networks, such as Cardiovascular System Development and Function, Cellular Growth and Proliferation and Cell Morphology. TGFB1 is a multifunctional peptide that controls proliferation, differentiation, and other functions in many cell types. In our study, TGFB1 was significantly up-regulated by estradiol as a main effect, supporting its important role in cardiovascular function. According to our results, estradiol exerts an important role in vessel assembly and stabilization through TGFB signaling pathways [@pone.0008242-Soares2]. Moreover, TGFB pathway status determines the antiatherogenic effect of estradiol in apoE-/- hypercholesterolemic mice [@pone.0008242-Gourdy1]. Furthermore, estradiol administration to postmenopausal women increases circulating levels of the active form of TGFB1 [@pone.0008242-Djurovic1]. Altogether, these findings led to the conclusion that TGFB1 is one of the main targets of estradiol stimulation.

With the use of ICI 182780 in some experiments, our study demonstrates that activation of ER by E2 modifies the expression of several genes in HUVEC. In spite of some authors have found that HUVEC do not express ERα [@pone.0008242-Toth1], other investigators have demonstrated the presence of both ERα and ERβ mRNA in HUVEC [@pone.0008242-Wagner1]. Data presented in [Figure 7](#pone-0008242-g007){ref-type="fig"} demonstrate the expression of both ERα and ERβ protein in HUVEC, thus confirming previous reports [@pone.0008242-Oviedo1], [@pone.0008242-Harris1].

The extensive information gained from this first analysis has resulted in the collection of new data and new genes that provide other opportunities of study not explored so far, for example, the increased expression of the DHCR7 gene when HUVEC were exposed to different estradiol concentrations. This gene is responsible for the last step in cholesterol synthesis, and its inhibition results in hypocholesterolemia and accumulation of 7-dehidrocholesterol [@pone.0008242-KolfClauw1], while different mutations of this gene cause the Smith-Lemli-Opitz syndrome [@pone.0008242-WitschBaumgartner1]. In our study, DHCR7 expression induced by 1 nmol/L estradiol was completely abolished in the presence of ICI182780 ([Figure 5D](#pone-0008242-g005){ref-type="fig"}). This is similar to the unique description of the relationship between this gene and estradiol, in which the expression of DHCR7 on human osteosarcoma cells was increased in response to estradiol through receptor beta [@pone.0008242-Monroe1].

Other cardiovascular-relevant genes confirmed the consistency of microarray data. Thus, the results are in accordance with similar effects observed in endothelial cells, both measuring the gene or the protein expression. COX are the rate-limiting step in the formation of vasoactive prostanoids, such as prostacyclin and thromboxane, from arachidonic acid [@pone.0008242-Smith1]. Our results point to an estradiol-induced, dose-dependent gene expression, resulting in increased protein expression of COX-1 without effect on COX-2, which in turn resulted in increased prostacyclin production. These data, mediated through ER activity, have already been reported in some studies performed in ovine pulmonary artery endothelial cells [@pone.0008242-Jun1], but not in others [@pone.0008242-Hermenegildo2]. Related to COX-mediated prostanoid production, cytosolic phospholipase A2 activity is the initial step which liberates arachidonic acid from the cell membrane. In our study, PLA2G4B expression was reported to be dose-dependent increased by estradiol, while the main subtype PLA2G4A remained unaltered. Previous studies have reported an increase in cytosolic phospholipase A2 protein expression, without subtype differentiation, in ovine [@pone.0008242-Rupnow1] and rat [@pone.0008242-Farina1] uterine arteries exposed to estradiol.

ADMA is an analogue of arginine, which is synthesized endogenously and can act as inhibitor of nitric oxide synthase [@pone.0008242-Vallance1]. Both DDAH are responsible *in vivo* for ADMA degradation to citrulline and dimethylamine. According to the results obtained in the microarray analysis and confirmed by QRT-PCR and inmunoblotting, DDAH2 is increased in HUVEC exposed to different concentrations of estradiol, whereas DDAH1 remains unaltered. DDAH2, the main subtype in the cardiovascular system, has already been reported to be increased by estradiol in endothelium [@pone.0008242-Monsalve1]. Moreover, the increased DDAH2 expression resulted in decreased ADMA concentration and therefore, increased NO release. Results of the present work further support that increased DDAH2 expression is dependent on ER-dependent genomic activity.

The strength of the current study is the careful design of the experiments and the use of sample pools which contribute to minimizing inter-individual variations. The average fold-change induced by estradiol is relatively low, but it should be taken into account that cells were exposed to estradiol concentrations that were within physiological levels in premenopausal women [@pone.0008242-Hermenegildo3]. Moreover, fold-changes and number of up-regulated genes in our study were within the same range as that obtained in similar studies performed with higher estradiol concentrations (10--50 nmol/L) in different human breast cancer cell types [@pone.0008242-Cicatiello1].

Care should be taken determining clinically relevant consequences. Much *in vitro* and *in vivo* experimental data support a beneficial effect of estrogens on the cardiovascular system [@pone.0008242-Turgeon1]. Observational studies have also consistently shown a benefit of hormone replacement therapy on cardiovascular disease, but some randomized studies have shown even some deleterious effects [@pone.0008242-Turgeon1], [@pone.0008242-Stevenson1]. New experimental approaches, such as the present study, should contribute to conciliate the divergences observed between clinical and experimental data.

In summary, our study generates a comprehensive estradiol-mediated gene expression profile in HUVEC and characterizes in detail the considerably different responses of control and estradiol-treated endothelial cells. The present study provides the first quantitative large-scale gene expression analysis of estradiol--stimulated human vascular endothelial cells. Identification of pathways regulated by estradiol may add to the knowledge base of how estradiol contributes to a wide range of biological processes. These results could lead to a deeper understanding of fundamental insights of pathophysiological mechanisms involved in cardiovascular diseases such as stroke or atherosclerosis at the level of gene expression and provide a foundation for the development of better therapeutic strategies for vascular disease.
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